Combination of Zibotentan and Dapagliflozin for Treatment of Chronic Kidney Disease and Liver Fibrosis
Summary
USPTO published patent application US20260097057A1 covering fixed-dose combination therapy using zibotentan and dapagliflozin for treating chronic kidney disease and liver fibrosis. The application, filed October 8, 2025, names Philip Ambery as inventor and discloses methods of treatment using the combination.
What changed
USPTO published patent application US20260097057A1 for a fixed-dose combination of zibotentan and dapagliflozin for treating chronic kidney disease and liver fibrosis. The application covers therapeutic methods using this drug combination.
Affected parties including pharmaceutical manufacturers developing competing nephrology or hepatology therapies should review freedom-to-operate implications. Patent issuance, if granted, would provide exclusivity for the combination therapy method of treatment.
What to do next
- Monitor for USPTO patent grant status
- Review freedom-to-operate implications for competing CKD treatments
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS
Application US20260097057A1 Kind: A1 Apr 09, 2026
Inventors
Philip Ambery
Abstract
Methods for treating chronic kidney disease and liver fibrosis in patients using a fixed-dose combination of zibotentan and dapagliflozin are disclosed.
CPC Classifications
A61K 31/7034 A61K 31/497 A61P 1/16
Filing Date
2025-10-08
Application No.
19352788
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.